research
A 200,000-Patient Study Finds No GLP-1 Link to One Eye Disease
First-time users showed no statistically significant change in neovascular macular-degeneration risk.
Summary
First-time users showed no statistically significant change in neovascular macular-degeneration risk.
Johns Hopkins compared records from 12 databases for adults starting GLP-1 drugs or comparators. More than 200,000 first-time semaglutide users plus other cohorts showed no significant increase or decrease in new neovascular AMD. The retrospective study concerns one eye condition and should not guide medication changes without a clinician.
Why it matters
First-time users showed no statistically significant change in neovascular macular-degeneration risk.
Limits and context
- The retrospective study concerns one eye condition and should not guide medication changes without a clinician.
Key claims
First-time users showed no statistically significant change in neovascular macular-degeneration risk.
Qualification: The retrospective study concerns one eye condition and should not guide medication changes without a clinician.
Evidence: source-2026-07-17-016
Sources
- Johns Hopkins via Newswise: GLP-1 and eye diseaseJohns Hopkins via Newswise · secondary reporting
Corrections
No corrections have been recorded for this story.